{"id":"NCT01982240","sponsor":"Bausch Health Americas, Inc.","briefTitle":"12-Week Study of Plecanatide for CIC (The CIC3 Study)","officialTitle":"A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation (The CIC3 Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11","primaryCompletion":"2015-04","completion":"2015-06","firstPosted":"2013-11-13","resultsPosted":"2019-03-21","lastUpdate":"2019-12-26"},"enrollment":1394,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Idiopathic Constipation"],"interventions":[{"type":"DRUG","name":"Plecanatide","otherNames":["Trulance"]},{"type":"DRUG","name":"Placebo","otherNames":["Trulance placebo"]},{"type":"DRUG","name":"Bisacodyl","otherNames":["Dulcolax"]}],"arms":[{"label":"Plecanatide 3.0 mg","type":"ACTIVE_COMPARATOR"},{"label":"Plecanatide 6.0 mg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Bisacodyl","type":"OTHER"}],"summary":"The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.","primaryOutcome":{"measure":"Number of Durable Overall CSBM Responders , Mean Replacement Approach","timeFrame":"12-week Treatment Period","effectByArm":[{"arm":"Placebo","deltaMin":46,"sd":null},{"arm":"Plecanatide 3.0 mg","deltaMin":95,"sd":null},{"arm":"Plecanatide 6.0 mg","deltaMin":86,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":189,"countries":["United States","Canada"]},"refs":{"pmids":["37162147","35086735","32660770","28169285"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":458},"commonTop":["Diarrhoea","Sinusitis","Nasopharyngitis"]}}